恒瑞医药：子公司获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276) announced on August 13 that its subsidiaries, Suzhou Shengdiya Biopharmaceutical, Shanghai Heng Rui Medicine, and Shanghai Shengdi Medicine, received approval from the National Medical Products Administration for the clinical trial of SHR-A2102 and Adebeli monoclonal antibody injection, which will commence shortly [1] Group 1 - The approval includes the clinical trial notification for SHR-A2102 and Adebeli monoclonal antibody injection [1] - The clinical trials are expected to begin in the near future [1]